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The low efﬁciency of gene transfer is a recurrent problem in DNA vaccine development and gene therapy
studies using non-viral vectors such as plasmid DNA (pDNA). This is mainly due to the fact that during
their trafﬁc to the target cell's nuclei, plasmid vectors must overcome a series of physical, enzymatic and dif-
fusional barriers. The main objective of this work is the development of recombinant proteins speciﬁcally
designed for pDNA delivery, which take advantage of molecular motors like dynein, for the transport of
cargos from the periphery to the centrosome of mammalian cells. A DNA binding sequence was fused to
the N-terminus of the recombinant human dynein light chain LC8. Expression studies indicated that the fu-
sion protein was correctly expressed in soluble form using E. coli BL21(DE3) strain. As expected, gel perme-
ation assays found the puriﬁed protein mainly present as dimers, the functional oligomeric state of LC8. Gel
retardation assays and atomic force microscopy proved the ability of the fusion protein to interact and con-
dense pDNA. Zeta potential measurements indicated that LC8 with DNA binding domain (LD4) has an en-
hanced capacity to interact and condense pDNA, generating positively charged complexes. Transfection of
cultured HeLa cells conﬁrmed the ability of the LD4 to facilitate pDNA uptake and indicate the involvement
of the retrograde transport in the intracellular trafﬁcking of pDNA:LD4 complexes. Finally, cytotoxicity stud-
ies demonstrated a very low toxicity of the fusion protein vector, indicating the potential for in vivo applica-
tions. The study presented here is part of an effort to develop new modular shuttle proteins able to take
advantage of strategies used by viruses to infect mammalian cells, aiming to provide new tools for gene ther-
apy and DNA vaccination studies.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Gene therapy and DNA vaccination protocols demand efﬁcient and
safe mechanisms to deliver therapeutic genetic material to the pa-
tient cell nucleus. So far, viral-based vectors have been preferred as
delivery vehicles since they are naturally efﬁcient in receptor-
mediated recognition and cell internalization, endosomal escape, nu-
clear transport and DNA integration [1,2]. Nevertheless, the use of vi-
ruses as gene delivery systems continues to rise safety concerns and
the future development of viral gene therapy continue to generate in-
tense scientiﬁc debates [2,3]. The alternative approach, non-viral vec-
tors, is considered safer and has been also attracting signiﬁcant
attention of the scientiﬁc community. Efforts have been made to
increase the delivery efﬁciency of non-viral vectors, including the cre-
ation of sophisticated vehicles able to mimic some of the viral proper-
ties regarding both size and biological properties [2]. These vectors
are called “artiﬁcial viruses” and include polymeric constructs [4–6],
protein-only shells and virus-like particles [4]. Among the properties
of these vectors are the ability to condense and protect DNA from nu-
clease degradation, low systemic and cellular toxicity, membrane
crossing abilities, and steady expression of the therapeutic gene [7].
However, the inability of these vectors to efﬁciently traverse the tar-
get cell cytoplasm and reach the nucleus has largely been overlooked
[8]. It has been also reported that non viral vectors face several extra-
and intracellular barriers before DNA can be delivered to the cell's nu-
cleus [9] and that cytosolic proteins may bind to the delivery complex
acting as another barrier [10].
The majority of the non-viral vectors studied so far rely on passive
diffusion or non speciﬁc transport for trafﬁcking within the cyto-
plasm, and this limited mobility represents a signiﬁcant barrier to
gene delivery [11]. Since it has been shown that diffusion of DNA
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fragments larger than 2000 base pairs through the crowded cytoplas-
mic environment is greatly restricted [12], an ideal vector should, like
most viruses, include the ability to exploit the host cell machinery to
rapidly traverse the cytoplasm. Many authors have suggested that an
ideal form to actively transport drugs, including transgenes, from the
site of cytoplasmic entry to the nuclear periphery would include re-
cruitment of the minus end-directed motor dynein [8,13–15]. Cyto-
plasmic dynein is a multisubunit protein complex (~1.2 MDa)
composed of two heavy chains (~530 kDa) responsible for microtu-
bule attachment and ATP hydrolysis [16], two 74-kDa intermediate
chains (IC74), four light intermediate chains (52–61 kDa), and several
light chains (10–25 kDa) which are responsible for cargo attachment
to the dynein motor complex and hence, its transport through the cy-
tosol toward the nucleus [17,18]. However, so far no successful strat-
egies to exploit motor proteins' retrograde transport for efﬁcient gene
delivery have been demonstrated. In an attempt to design synthetic
gene carriers that display dynein-binding peptides for enhanced in-
tracellular transport, Bergen and Pun (2007) studied the use of a pep-
tide that binds to the dynein light chain LC8 subunit, as the ﬁrst
potential dynein-binding peptide [8]. It was demonstrated that,
while the peptide readily bound free LC8, it could not bind to
dynein-associated LC8, emphasizing the need to identify or design
peptides that could mediate binding to the intact dynein motor com-
plex. More recently, Moseley and collaborators (2010) reported that
protein transduction can be enhanced by attachment to a dynein
light chain association sequence [15]. These sequences were able to
enhance nuclear accumulation of GFP-fusion proteins, with depen-
dence on the LC8/microtubule (MT) network. This work provided
the ﬁrst successful evidence that dynein/MT-association can be
exploited for DNA or drug delivery approaches.
Here, we propose the use of the dynein light chain LC8 itself as a
cargo adaptor for plasmid delivery into mammalian cells, taking ad-
vantage of the dynein retrograde transport via the MT network. LC8,
also called DYNLL1, is a small (10 kDa) and highly conserved globular
protein reported as an essential component of the dynein and myosin
V molecular motors [19,20]. The LC8 binds as a dimer directly to spe-
ciﬁc sites on the dynein intermediate chain IC74 or myosin V heavy
chain, while some studies indicate additional roles for LC8 in multiple
protein complexes unrelated to the motor proteins such as p53-
binding protein 1 [21], neuronal nitric oxide synthase [22], the proa-
poptotic member of the Bcl-2 family proteins Bim and Bmf [23,24],
the product of the Drosophila swallow gene [25], and a number of
proteins with unknown functions [26]. We envision that LC8 could
be modiﬁed with short DNA-binding sequences, rich in positively
charged amino acids, which would interact and condense pDNA and
facilitate its transport toward the nucleus periphery via interaction
with the dynein complex. Finally, the work presented here intends
to generate new information on plasmid delivery and presents a
new strategy for the development of modular non-viral vectors po-
tentially useful for gene therapy and DNA vaccination.
2. Materials and methods
2.1. Plasmid DNA vector
In the present study, a plasmid DNAmodel named pVAX1-Luc was
constructed based on the previously reported pVAX1-GFP plasmid
[27]. Using XbaI and EcoRI restriction endonucleases, the sequence
coding for GFP was replaced by the luciferase gene obtained from
the pGL3-Luc control vector (Promega) using the same restriction en-
zymes. The success of the reporter gene replacement was conﬁrmed
by the expression of the reporter enzyme after transfection of HeLa
cells, as described in this work. Puriﬁcation of the pVAX1-Luc plasmid
used in all transfection studies was performed as described by Freitas
and co-workers [28].
2.2. DNA binding domains design
The fusion protein DNA binding domainswere designed based on the
scientiﬁc literature available [2,29] for peptides and protein domains
with high DNA binding and condensing capacity. We designed four do-
mains to be cloned upstream of human dynein light chain LC8: DNAb1,
WRRRGHGKKK; DNAb2, WRRRGFGKKK; DNAb3, WRRRGHGRRR; and
DNAb4, WRRRGFGRRR. The corresponding single strand oligonucleo-
tides were synthesized with optimized codons for E. coli expression
and annealed before cloning. The DNA binding domains were cloned in
the NdeI and BamHI sites in the pET28a expression vector (Novagen,
Darmstadt, Germany). The clones containing the DNA binding domains
were further used for LC8 cloning in the BamHI and XhoI restriction
sites. In this work we deﬁne as LD4 the recombinant human LC8 fused
to the DNA binding domain 4 (DNAb4), described above.
2.3. Recombinant proteins expression and puriﬁcation
The human dynein light chain LC8 was ampliﬁed from HeLa cDNA
with speciﬁc primers (forward:5´-ATAGGATCCATGTGCGACCGAAAG-3´,
reverse: 5´ATACTCGAG TTAACCAGATTTGAACAGAAGA-3´) and cloned
into pET28a with and without DNA binding domains previously cloned
at the N-terminal. Recombinant LC8 with or without DNA binding do-
mains were expressed in E. coli BL21(DE3). Brieﬂy, cells were grown in
1 L LB medium at 37 °C, 300 rpm and up to an optical density of 0.8 AU
(600 nm). Protein expression was induced with 5.6 mM lactose or
0.2 mM IPTG (isopropyl-β-D-thiogalactopyranoside) for further 12 h at
25 °C, 200 rpm. After centrifugation, the cell pellet was suspended in
50 mM sodium phosphate pH 8.0, 500 mM NaCl, 0.1 mM EDTA, 15 mM
β-mercaptoethanol and 1 mM PMSF (phenylmethylsulfonyl ﬂuoride).
Cell lysis was performed by sonication and the recombinant LC8was pu-
riﬁed by a single Ni-NTA afﬁnity chromatography step. This method was
successfully used to purify recombinant LC8 with and without the four
different DNA binding domains.
For in vitro interaction of recombinant dynein light chain LC8 and
LD4 with human dynein intermediate chain DYNIC2 its N-terminal
domain (the ﬁrst 300 amino acids) and the dynein light chain TcTex
were cloned using the same methodology as described for LC8. The
DYNIC2 domain was ampliﬁed with speciﬁc primers from HeLa
cDNA and cloned into pET28a using NdeI and BamHI restriction
sites (forward, 5´-ATTCATATGATGTCAGACAAAAGTGAATT-3´, reverse,
5´-ATTGGATCCTTAGTTATAGGAAGCCAC-3´). The TcTex light chain
was inserted in BamHI and XhoI restriction sites (forward, 5´-ATAG-
GATCCATGGAGGAGTACCATCG-3´, reverse, 5´-ATACTCGAGTTAAA-
GAACAATAGCAATGG-3´). Both recombinant proteins were expressed
in E. coli BL21 (DE3) Rosetta strain. The expression of the N-terminal
DYNIC2 was induced with 0.2 mM IPTG at 20 °C and 200 rpm for 12 h.
For all recombinant proteins, purity was evaluated by SDS-PAGE and
concentration was measured by absorbance at 280 nm.
2.4. Circular dichroism studies
Circular dichroism (CD) spectra of the puriﬁed recombinant pro-
teins were obtained using a Jasco J-810 Spectropolarimeter dichro-
graph (Japan Spectroscopic, Tokyo, Japan). The far-UV CD spectra
were generated at 20 °C using 10–20 μM of each protein in 10 mM so-
dium phosphate buffer pH 8.0. The assays were carried out using a
quartz cuvette with a 1 mm path length. Ten accumulations within
the 185–260 nm range at a rate of 50 nm/min were recorded. Data
was processed using OriginLab 8.0 software.
2.5. Size exclusion chromatography
To assess the oligomeric state of puriﬁed LC8 with and without DNA
binding domains, size exclusion chromatography was performed using
a Superdex 200 GL10/300 or Superdex 75 GL10/300 prepacked column
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(GE Healthcare, Uppsala, Sweden). After equilibration of the column
with extraction buffer or PBS (8.0 g NaCl, 0.2 g KCl, 1.4 g Na2HPO4,
0.24 g KH2PO4, pH 7.4 per liter), oxidized and reduced (10 mM DTT)
samples (250 μl) were loaded at a ﬂow rate of 0.75 ml/min. The calibra-
tion curve was prepared using High and Low molecular calibration kits
(GE Healthcare). Gel permeation chromatography was also used to
evaluate LC8-TcTex-Intermediate chain complex formation.
2.6. In vitro interaction of recombinant dynein light chains LC8 and TcTex
with dynein intermediate chain 2, isoform C
In order to evaluate the ability of recombinant LC8 and LD4 to in-
teract in vitrowith the human dynein intermediate chain DYNIC2, iso-
form C, the N-terminal of this protein (ﬁrst 300 amino acids) was
cloned, expressed and puriﬁed as described. We also used in this
assay the TcTex light chain since its presence in the complex may en-
hance the interaction between LC8 and the intermediate chain, as dis-
cussed in the Results and discussion section. LC8 (19.2 μM) or LD4
(8.9 μM) and TcTex (6.3 μM) light chainswere incubatedwith puriﬁed
intermediate chain domain, ICDOM (7.23 μM), at 8 °C for 20 h under re-
ducing conditions (10 mM DTT). The puriﬁed proteins were used im-
mediately after puriﬁcation procedure and complex was formed in
50 mM sodium phosphate pH 8.0, 500 mM NaCl, 0.1 mM EDTA and
approximately 200 mM imidazole. Complex formation was evaluated
by gel permeation chromatography using a Superdex 75 GL10/300
prepacked column (GE Healthcare, Uppsala, Sweden) and collected
samples corresponding to the complex elution peakswere concentrat-
ed (10-fold concentration) using a Amicon Ultra Centrifugal Filter
(3 kDa) (Millipore, Ireland) and visualized by SDS-PAGE.
2.7. Evaluation of DNA-protein interaction by gel retardation assay
To evaluate the ability of LC8, LC8 with different DNA binding do-
mains and protamine to interact and condense pDNA, we performed a
gel retardation assay. Proteins were dialyzed in PBS (protamine sul-
fate powder was ressuspended in PBS) and incubated with 250 ng
of pVAX-Luc vector (previously in PBS) at different pDNA:protein
molar ratios (1:400, 1:800, 1:1000, 1:2000, 1:4000 and 1:8000) in a
ﬁnal volume of 50 μL. The samples were incubated at room tempera-
ture for 1 h following by the addition of 50 μL of non supplemented
F-12 media and additional incubation for 20 min. Samples were run
in a 0.8% agarose gel and visualized by ethidium bromide staining.
2.8. Zeta potential and particle size assays
Zeta potential measurements were performed to comparatively
evaluate the surface charge of complexes formed by pDNA:LC8 and
pDNA:LD4. Complexes were formed as described for gel retardation
assay but without F-12 media addition and using the same pDNA:pro-
tein molar ratios. Each sample was measured in triplicate using Zeta-
sizer 3000 (Malvern, England). Particle size measurements were
performed to evaluate the behavior of different complexes regarding
its size along time. pDNA:protamine (pDNA:protein molar ratio of
1:8000) and pDNA:LD4 (pDNA:protein molar ratio of 1:100 and
1:8000) complexes with and without Lipofectamine™ and pDNA:
Lipofectamine™ complexes were formed by 1.0 μg of pDNA and the
corresponding amount of protein in a ﬁnal volume of 800 μL. When
indicated, 1.5 μL of Lipofectamine™ was added to the complex. Each
sample was submitted to multiple readings during a 60 min period.
Particle diameter was plotted against time for each sample.
2.9. Atomic force microscopy (AFM)
Plasmid DNA:protein complexes at different molar ratios (1:400,
1:1000 e 1:2000 for LC8 and 1:100, 1:200 e 1:500 for LD4) were pre-
pared in 10 mM Tris–HCl buffer pH 7.4 in a ﬁnal DNA concentration of
600 pg/μl by incubation at room temperature for 1 h. After complex for-
mation, a ﬁnal concentration of 5 mMMgCl2 was added to each sample
and 60 μl of the solution was physisorbed for 1 min on freshly cleaved
muscovitemica (Ted Pela, California, USA). After adsorption, the surface
was washed for 10 s in ultrapure water and dried in a weak nitrogen
stream. The AFM imaging was performed in air a room temperature in
acoustic mode at a scanning speed of 300 nm/s with an Agilent 5500
(Agilent, Santa Barbara, USA) using commercial silicon cantilevers
(MicroMash, NSC-14/ALBS) with a tip radius of approximately
10–20 nm. The topography images were treated using the Open-
Source software Gwyddion (www.gwyddion.net).
2.10. Culture and transfection of HeLa cells
HeLa cells were grown in F-12 (Ham) nutrient mixture (Gibco, UK)
containing 10% (v/v) fetal bovine serum (growth medium, Gibco, UK).
All cell cultures were performed in 75 cm2 culture ﬂasks and incubated
in 5% CO2 humidiﬁed environment at 37 °C. Following growth up to
conﬂuence, cells were trypsinized and seeded in 24 well culture plates
(5×104 cells per well). The cells were incubated for 48 h (to a 70% con-
ﬂuence) and then transfected with pDNA:protein complexes formed as
described for gel retardation assays and using the same molar ratios.
When indicated, transfection was carried out using the Lipofectamine
2000™ reagent (Invitrogen, USA) according to the manufacturer in-
structions (1.0 μg pDNA plus 1.5 μL reagent in 100 μL of medium per
well), protamine sulfate (SigmaAldrich, Germany) or PEI (polyethyleni-
mine, branched, MW ~25,000) (Sigma Aldrich, Germany). Themedium
containing the transfection solution remained on the cell containing
wells for 6 h and was then replaced by regular growth medium. Cells
were collected after 24 h post-transfection for determination of lucifer-
ase activity using the luciferase Assay System (Promega, USA), following
the manufacturer's instructions. Luminescence intensity was normal-
ized against protein concentration in each transfection sample, as deter-
mined by the Micro BCA Protein Assay Kit (Thermo Scientiﬁc, USA).
To evaluate the contribution of themicrotubule network and actin ﬁl-
aments in the intracellular trafﬁcking of the complexes, cells were pre-
incubated for 2 h with nocodazole (25 μM) or cytochalasin D (25 μM)
for microtubule and actin ﬁlaments disruption, respectively. Both drugs
were dissolved in DMSO and an equal volume of drug-free DMSO was
used as control (0.5% for cytochalasin D and 0.4% for nocodazole). Trans-
fections in the presence of chloroquine were performed to evaluate the
contribution of lysosomal degradation of protein-pDNA complexes.
Cells were pre-incubated for 4 h with chloroquine (100 μM). For all as-
says with the mentioned drugs, pre-treated cells were incubated after-
wards in the presence of the different complexes for 4 h, when the
medium was replaced by freshly growing medium. After 24 h, cells
were collected and the luciferase activitywas assayed as described above.
Cytotoxicity assays of delivery vectors studied in the present work
were performed using Cell Proliferation ReagentWST-1 (Roche Applied
Science, USA) following manufacturer's instructions. Brieﬂy, HeLa cells
were grown on 96 wells plates to a conﬂuence of 70%. Transfection
was performed as described before with pDNA:protein complexes
(molar ratio of 1:8000) with and without Lipofectamine™, with
pDNA:Lipofectamine™, and also with naked pDNA as control. Finally,
10 μL of the WST-1 reagent was added to each well, and cells were fur-
ther incubated for 2 h. Absorbance was read after 60 s agitation at
440 nmusing a Spectramax 384 Plus UV/VISMicroplate Reader (Molec-
ular Devices, USA).
3. Results and discussion
3.1. Recombinant human dynein light chain LC8 was successfully
produced with N-terminal DNA binding domains
Using the methodology described above we were able to produce
recombinant LC8 and recombinant LC8 fused to DNA binding domains
224 M.A.S. Toledo et al. / Journal of Controlled Release 159 (2012) 222–231
G
E
N
E
D
E
L
IV
E
R
Y
(DNAb1, DNAb2, DNAb3 and DNAb4), all proteins efﬁciently
expressed in E. coli BL21(DE3) strain. All constructs were obtained
in the soluble fraction after cell disruption and puriﬁed by a single
Ni-NTA afﬁnity chromatography step (Fig. 1). Circular dichroism
analysis of the secondary structures of the proteins showed that
addition of the DNA binding domains had little effect on the second-
ary fold of LC8 probably due to the addition of the domain to its
N-terminal (Fig. 2 and Supplementary Data). The oligomeric state
of LC8 and LC8 fused with DNAb4 (LD4) was evaluated in phosphate
saline buffer (PBS) by gel permeation chromatography under re-
duced and non reduced conditions. We could observe that the
human LC8 is dimeric under reducing conditions, as reported for
the Drosophila homologue [30], and appears as a tetramer under
non reducing conditions (results not shown). The LD4 presented a
higher propensity to aggregate under low ionic strength (such as
in PBS), as judged by the fact that a signiﬁcant portion of the puri-
ﬁed protein precipitated during dialysis against PBS, even under
reducing conditions. Gel permeation chromatography shows that
LD4 in PBS under reducing and non reducing conditions is polidis-
persed in diverse oligomeric subpopulations. However, analysis of
small angle X-ray scattering (SAXS) data for Lc8 and LD4, collected
in 50 mM sodium phosphate, 500 mM NaCl, 0.1 mM EDTA and
500 mM Imidazole, allowed us to assume that the recombinant
proteins were folded in solution under reducing conditions. A bell
shaped Kratky plot was observed, which is characteristic of folded
proteins (Supplementary Data). Therefore, the observed aggrega-
tion for LD4 may be due to the relative low ionic strength of PBS. In
summary, our results indicate that the recombinant LC8 and its
variations with different DNA binding domains were successfully
and correctly expressed and puriﬁed (Fig. 1) allowing us to proceed
with pDNA interaction and transfection assays. It is noteworthy that
LD4 (as well with other DNA binding domains), despite appearing as
a population of aggregates in gel permeation assays, was successfully
used in pDNA condensation assays, indicating that upon DNA addi-
tion, the protein aggregates were disrupted allowing protein inter-
action with the pDNA.
3.2. Recombinant LC8 and LD4 are able to interact in vitro with human
dynein intermediate chain
The human LC8 dynein light chain interacts with the dynein inter-
mediate chain and some other proteins not related to the dynein
motor complex as mentioned before (see Introduction). Additionally,
the interaction between LC8, TcTex and the intermediate chain IC74 is
well characterized for the Drosophila homologues. In a recent work,
Hall and collaborators (2009) showed that when one of the light
chains (LC8 or TcTex) is previously bound to the intermediate chain
IC74, the binding of the second light chain is enhanced by 50-fold
[31]. In the context of the gene delivery mechanism envisioned in
Fig. 1. SDS-PAGE analysis of puriﬁed recombinant proteins used in the present study. A: Puriﬁed LC8. B: Puriﬁed LD4. C: Puriﬁed intermediate chain N-terminal domain. D: Puriﬁed
TcTex. E: LC8 and LC8 with the four different DNA binding domains at the N-terminal after dialysis against PBS. M: Broad Range molecular weight marker (Fermentas). Ins: Insoluble
fraction after cell lysis. Sol: Soluble fraction after cell lysis. LC8pur: puriﬁed LC8. LD4pur: puriﬁed LD4. Dompur: puriﬁed N-terminal domain of DYNIC2 intermediate chain. TcTexpur:
puriﬁed TcTex. LC8, LD1,LD2,LD3,LD4: LC8 without and with each DNA binding domain.
Fig. 2. Circular dichroism curves for dynein light chain LC8 and for LC8 fused with DNA
binding domain 4. LC8: LC8 dynein light chain. LD4: LC8 dynein light chain fused with
DNAb4 binding domain. Little variation between the spectra can be observed probably
due to the addition of the DNA binding domain.
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the present work, the recombinant dynein light chain LC8, whether
fused or not to DNA binding domains, should be able to interact
with the dynein machinery. Thus, in order to analyze the functionality
of recombinant LC8 and LD4, we assayed their interaction with the N-
terminal domain (300 ﬁrst amino acids) of the human dynein inter-
mediate chain 2, isoform C (DYNIC2), in combination with TcTex dy-
nein light chain. We could observe that both, LC8 and LD4 were able
to interact in vitro with dynein intermediate chain by gel permeation
chromatography and subsequent SDS-PAGE analysis of the eluted
peak (Fig. 3). This result shows that the recombinant LC8 light
chain, with or without the N-terminal DNA binding domain retains
its functionality once it is able to interact with human intermediate
chain in vitro.
3.3. Addition of DNA binding domains at the N-terminal of LC8 light
chain leads to enhanced interaction and condensation of plasmid DNA
A gel retardation assay was performed to evaluate the effect of
DNA binding domains on the LC8 ability to interact and condense
pDNA. We tested the same gradient of DNA:protein molar ratio for
all DNA binding constructs, for LC8 alone and used protamine as con-
trol. Despite being non quantitative, this assay clearly shows an en-
hanced capacity of LC8 with DNA binding domains to interact and
condense pDNA when compared to LC8 alone or to protamine
(Fig. 4). At low pDNA:protein molar ratios (1:400), shifted bands
can be observed for all constructs with DNA binding domains where-
as only at higher molar ratios (1:2000) some shift can be observed for
LC8 alone and for protamine. In addition, at higher molar ratios
(1:4000), uncomplexed pDNA can still be observed for LC8 whereas
for LC8 with DNA binding domains, all pDNA is complexed and has
its migration retarded.
3.4. LC8 with DNA binding domain 4 interacts with pDNA generating
positively charged complexes
An efﬁcient vector for gene delivery must mediate the condensa-
tion and uptake of the genetic material by the cell. Speciﬁcally, the de-
livery vector must help to overcome the charge incompatibility
between the negatively charged cell surfaces and pDNA molecules,
by generating complexes with a positive net charge. We thus evaluat-
ed the surface charge of complexes formed between pDNA and LC8 or
LD4. Zeta potential of pDNA-protein complexes was measured at dif-
ferent pDNA:protein molar ratios (Fig. 5A). The plot of zeta potential
against each molar ratio shows that the addition of the DNA binding
Fig. 3. Interaction of recombinant LC8 and LC8 with DNA binding 4 with the N-terminal
domain of DYNIC2 and with the dynein Light Chain Tctex. A: Gel permeation chroma-
tography elution curves for LC8-DYNIC2-TcTex. B: Gel permeation chromatography
elution curves for LD4-DYNIC2-TcTex. C: SDS-PAGE 15% for elution samples from gel
permeation chromatography showing that DYNIC2 and Light Chains are eluted togeth-
er indicating interaction. Dom: puriﬁed N-terminal domain of Intermediate Chain (pre-
mature translation end can be observed for this protein). LC8: puriﬁed LC8. LD4:
puriﬁed LD4. TcTex: puriﬁed TcTex. CLC8: elution peak collected at 9 ml and concentrat-
ed 10 fold for the LC8-DYNIC2-TcTex complex. CLD4: elution peak collected at 9 ml and
concentrated 10-fold for the LD4-DYNIC2-TcTex complex. Con: Control experiment,
elution peak collected at 9 ml and concentrated 10-fold for DYNIC2 alone.
Fig. 4. Protein–DNA interaction analysis by gel retardation assay. The ability of prot-
amine, LC8 and LC8 fused to DNAb1 (LD1), DNAb2 (LD2), DNAb3 (LD3) and DNAb4
(LD4) binding domains to interact and condense plasmid DNA was analyzed by a gel
retardation assay. Six pDNA:protein molar ratios were used (lanes 1 to 6): 1:400,
1:800, 1:1000, 1:2000, 1:4000 and 1:8000. C: control pDNA with no protein.
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sequence 4 to LC8 enabled the formation of complexes with positive
net surface charge when a molar ratio above 1:4000 was used. For
complexes formed with LC8 without DNA binding sequence, the net
surface charge remained negative in all molar ratios tested.
We also monitored the particle size of pDNA:protamine (1:8000
molar ratio) and pDNA:LD4 (1:8000 and 1:100 molar ratio) with
and without Lipofectamine™ and pDNA:Lipofectamine™ complexes
during 60 min of incubation at room temperature (Fig. 5B and C).
This analysis showed that addition of Lipofectamine™ to pDNA:pro-
tein complexes (LD4 or protamine) slightly increased the particle
size, especially in the ﬁrst 40 min of incubation. After that, pDNA:
LD4 complexes, in especial, presented a sharp increase in size, proba-
bly due to aggregation caused by the lack of electrostatic repulsion, as
indicated by the low values of zeta potential. Interestingly, the smal-
lest complex which also showed no signiﬁcant variation during the
analysis was pDNA:LD4 (1:100) with Lipofectamine™. Particle size
and particle surface charge are two main factors that dictates inter-
nalization of the delivery complex by the cell and is directly correlat-
ed to transfection efﬁciency [32,33]. Thus, by monitoring both
variables we are able to correlate and perhaps explain the results
found during transfection.
In order to evaluate the pDNA condensation, we performed atomic
force microscopy (AFM) assays. The methodology allowed us to visu-
alize the effect of the DNA binding domain 4 on the LC8 light chain af-
ﬁnity for the pDNA molecule. As it can be observed (Fig. 6), LD4
presented enhanced capacity to interact and condense plasmid DNA
in contrast to LC8. In excess of both pDNA binding proteins, the
pDNA:protein complexes form nearly spherical particles. In compari-
son, LD4 condenses pDNA to compact particles with sizes in the range
of 75±8 nm at lower molar ratios (1:500) than LC8 (1:2000) with
size in the range of 101±9 nm. However, it is important to note
that the complexes observed by this method were formed at a
lower ionic force and different buffer salt (10 mM Tris–HCl buffer)
than those shown in gel retardation and Zetasizer experiments
(PBS). The excess of salt in PBS buffer strongly affects the AFM imag-
ing procedure. Despite the difference in ionic strength that probably
lead to DNA condensation at lower pDNA:protein ratios, the AFM im-
ages clearly indicate the effect of the DNA binding domain.
3.5. Transfection experiments demonstrated that LD4 is able to deliver
pDNA to HeLa cells
After the interaction tests in vitro, we assayed the ability of the fu-
sion protein LD4 to deliver pDNA to HeLa cells in culture. Firstly, we
tested complexes formed by pDNA and recombinant LC8 with and
without the four different DNA binding domains. These preliminary
transfections assays showed that LD4 was the most efﬁcient shuttle
protein among all the constructs (results not shown). Therefore, we
focused our efforts on LD4, and used LC8 and the arginine rich prot-
amine as controls. The results show that LD4 is more efﬁcient in cell
transfection when compared to protamine (Fig. 7A), a well character-
ized nuclear protein that is known for its ability to condense DNA
molecules, facilitate DNA uptake by the cells, and transposition of
the nuclear barrier due to presence of a nuclear localization signal
[34,35]. LD4 mediated transfection presented a 30-fold higher lucifer-
ase expression compared to protamine at the same pDNA:protein
molar ratio (1:8000), while LC8 presented even lower efﬁciency (4-
fold lower than protamine). It is noteworthy that pDNA:LD4
(1:8000) complexes formed particles with bigger size than pDNA:
protamine (1:8000) complexes as shown by size measurements and
a mildly positive surface charge, as shown by Zeta potential measure-
ments. Therefore, the observed enhanced transfection efﬁciency pre-
sented by pDNA:LD4 complexes compared to protamine complexes
might be related to an additional property of the recombinant LD4
that facilitates pDNA delivery. Interestingly, when pDNA:LD4 com-
plexes were formed at a molar ratio of 1:16,000, the transfection efﬁ-
ciency dropped 3-fold. It is possible that the decrease in transfection
efﬁciency was caused by protein saturation and formation of bigger
complexes by non-speciﬁc protein–protein interaction leading to a
lower complex uptake by the cell [36].
We also tested multicomponent complexes formed by pDNA and
protein (LC8, LD4 and protamine), Lipofectamine™ or PEI (Fig. 7B).
Cationic lipids like Lipofectamine™ are known as efﬁcient pDNA de-
livery vectors in culture cells, enabling the internalization of several
thousand pDNA copies per cell during in vitro transfection [34]. As
expected, binary complexes formed by pDNA and Lipofectamine™
Fig. 5. A: Net surface charge of pDNA complexes formed by LC8 and LC8 fused to DNA
binding domain 4 (LD4). The zeta potential of pDNA:protein complexes was measured
at seven different molar ratios (1:200, 1:400, 1:800, 1:1000, 1:2000, 1:4000 and
1:8000). LD4 clearly shows higher ability to form positively charged complexes at
molar ratios above 1:4000, while LC8 alone generated negatively charged complexes
in all conditions tested. B and C: Time course of particle size for the different pDNA:de-
livery vector complexes studied.
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promoted higher transfection efﬁciencies than pDNA:protein com-
plexes (using either LD4 or protamine). Interestingly, ternary com-
plexes formed by pDNA, Lipofectamine and LD4 presented even
more efﬁcient pDNA delivery. In this case, we observed that in the
presence of Lipofectamine™, complexes formed at 1:100 pDNA:pro-
tein molar ratio were more efﬁcient than those formed at 1:8000.
One possible explanation is that addition of Lipofectamine™ to the al-
ready compact complex formed by pDNA:LD4 (1:100) lead to the for-
mation of more stable and even smaller complexes of approximately
100 nm, as can be seen in Fig. 5.
It is interesting to note that the addition of protamine to the terna-
ry complex (1:8000:8000 pDNA:LD4:protamine), resulting in the for-
mation of quaternary complexes, restored the transfection efﬁciency,
indicating that synergic effects between the lipid and proteins are re-
sponsible for the increase in transfection efﬁciency. The increase in
transfection efﬁciency promoted by protamine in multicomponent
complexes have already been reported and was credited to its nuclear
localization signal [35,37]. Despite this may also be the case of LD4,
the observed increase in pDNA delivery of complexes containing
LD4 at a low molar ratio (1:100) can also be explained by changes
in complex stability, size, and the ability to overcome different bar-
riers to the intracellular trafﬁcking, including the recruitment of dy-
nein motors. Synergic effects resulted from the combination of
proteins and the cationic polymer PEI were also observed (Fig. 7B).
Therefore, these multicomponent complexes may combine the high
capacity of pDNA internalization of the cationic lipids or polymers
with the enhanced capacity of transport through the cytoplasm and
nuclear entrance of the protein vectors.
3.6. Cytoskeleton and endossome/lysosome involvement in the
transfection efﬁciency of pDNA:LD4 complexes
Our expectation on the study of LD4 protein for pDNA delivery is
set on the possibility that this protein could mediate pDNA trafﬁcking
throughout the cytoplasm via dynein retrograde transport following
escape from endosomes. The insertion of a DNA binding domain at
the protein N-terminus was decided based on the structural data of
the LC8 protein, since interaction with the dynein motors occurs via
C-terminus and dimer interface [38]. Since the dynein motor complex
relies on the microtubule network to mediate the cellular transport,
the use of microtubule depolymerizing agents, such as nocodazole,
would abort the active transport resulting in the decrease of transfec-
tion efﬁciency.
Therefore, to evaluate the role of microtubules on pDNA:LD4 com-
plexes (1:8000 pDNA:protein molar ratio) mediated gene transfer
into HeLa cells, nocodazole was used. By using this drug, we observed
a 49% decrease in the transfection efﬁciency (Fig. 8). Similarly, cyto-
chalasin D was used to evaluate the effect of actin ﬁlaments disrup-
tion on transfection efﬁciency (Fig. 8). The disruption of the actin
ﬁlaments lead to a decrease in transfection efﬁciency of 99%. The re-
sults indicate that pDNA:LD4 complexes strongly rely on the cells cy-
toskeleton for intracellular trafﬁcking and pDNA delivery. However,
the decrease in transfection efﬁciency caused by the disruption of
the cytoskeleton has already been described in the literature using
pDNA:Lipofectamine™ and pDNA:PEI (polyethyleneimine) com-
plexes [39,40]. Despite microtubules tend to facilitate intracellular
trafﬁcking of vectors via active retrograde transport of the vesicles
formed after endocytosis, they can also contribute to their degrada-
tion since most of the vectors remain entrapped inside late endo-
somes and lysosomes and are ﬁnally destroyed in these vesicles
[41,42]. On the other hand, the observed decrease in transfection efﬁ-
ciency when cells were pre-treated with cytochalasin D can be cred-
ited to the role attributed to actin ﬁlaments in the early steps of
complex entry in the cell [40] as they are important to receptor-
mediated endocytosis and might be involved in other pathways of in-
ternalization [43]. Disruption of actin ﬁlaments tends to decrease the
internalization of complexes and hence lower transfection efﬁciency.
In order to further investigate the endosomal entrapment, which
stands as a limiting step for gene delivery efﬁciency [44] of the
pDNA:LD4 complexes, we performed transfections of HeLa cells trea-
ted with the lysosomotropic agent chloroquine (Fig. 8). Cloroquine is
a weak base that accumulates in acidic organelles such as late endo-
somes and lysosomes, raising the luminal pH of the organelles and
avoiding enzymatic degradation of non-viral vectors [45]. This drug
is frequently used to investigate the effect of the endosomal/lysosom-
al entrapment as a barrier to gene delivery, since its action causes a
Fig. 6. Visualization of pDNA:LC8 and pDNA:LD4 complexes by atomic force microscopy (AFM). pDNA:protein complexes formed at different molar ratios (1:400,1:1000 and 1:2000
for LC8 and 1:100, 1:200 and 1:500 for LD4) allowed us to visualize the condensation process mediated by the protein. This methodology clearly shows that addition of a DNA bind-
ing domain 4 to the LC8 Dynein Light Chain enhanced its ability to interact and condense plasmidial DNA.
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rise in intraendosomal osmolarity and its eventual lysis [46,47]. In our
case, pre-treatment of HeLa cells with chloroquine (100 μM) en-
hanced the LD4mediated transfection efﬁciency by 383%. Considering
this data, escape from endosomes and lysosomes seems critical for
the efﬁciency of LD4 mediated gene delivery and also for the under-
standing of the mechanisms of the intracellular trafﬁcking of these
pDNA:protein complexes. Beside this, we should also consider that
an early release of pDNA:LD4 complexes in the cytosol promoted by
chloroquine has another positive effect, since the complex may still
rely on the retrograde transport to get closer to the cell nucleus via di-
rect interaction between LD4 and dynein. In fact, we performed trans-
fections using pDNA:protamine complexes in the presence of
chloroquine and we found that the drug promoted an increase of
11-fold in Luciferase expression (Supplementary Data). Taking this
result into account, LD4 seems to be more efﬁcient in endosomal/ly-
sosomal escape than protamine.
Finally, since both, pDNA:LD4 and pDNA:protamine, complexes
used in this study have similar physical-chemical characteristics
(size, charge ratio, nature, etc.), we believe that the differences
found in transfection efﬁciency between LD4 and protamine mediat-
ed transfection (30-fold) may also be related to the natural ability of
the LD4 to interact with the dynein motor and facilitate the intracel-
lular trafﬁcking. A complete study of the differences in intracellular
trafﬁcking of the different complexes studied here is still in progress
by our research group. However, due to the complex nature of the
vectors and the diversity of cellular entry pathways and intracellular
trafﬁcking, this is a very challenging task.
3.7. Plasmid DNA:LD4 complexes presented reduced cytotoxicity when
compared to pDNA:Lipofectamine™ complexes
Cytotoxicity of the delivery vectors used in the present work was
evaluated using the Cell Proliferation Reagent WST-1 (Roche Applied
Science, USA) and cultivated HeLa cells. As expected, protein vectors
proved to be far less toxic (98% and 95% cell viability for LD4 and prot-
amine, respectively) than Lipofectamine™ (59% cell viability) (Fig. 9).
Interestingly, the combination of LD4 and Lipofectamine™ lead to a
reduced cell mortality comparing to the complex formed by cationic
lipid and pDNA. So far, it is not clear the mechanisms behind the re-
duction of toxicity caused by the presence of the proteins in the ter-
nary complexes. A possible explanation could be the reduction of
the cationic lipid content in these complexes caused by competition
with the proteins for the negatively charged plasmid backbone. Any-
way, an important attribute of a gene delivery vehicle is the low tox-
icity, opening the possibility for a secure in vivo utilization, and the
results indicate that pDNA:LD4 is a promising vector.
4. Conclusion
We presented here an innovative approach for the non-viral deliv-
ery of plasmid DNA. By combining the recombinant dynein light chain
LC8 with a synthetic N-terminal DNA binding domain we were able to
Fig. 8. Involvement of microtubules and endosomes/lysosomes on transfection efﬁ-
ciency of HeLa cells using LD4:pDNA complexes. The involvement of microtubules
and actin were studied using the drugs nocodazole and cytochalasin D, respectively.
The lysosomotropic agent chloroquine was used to investigate the effect of the endoso-
mal/lysosomal entrapment as a barrier to gene delivery. Experiments were performed
in triplicate as described in the Materials and methods section. Error bars indicate stan-
dard deviation between triplicates.
Fig. 9. Evaluation of the cytotoxicity of the different delivery vectors for HeLa cells per-
formed using WST-1 reagent (Roche Applied Science). We assayed the cell viability
after transfection with complexes formed by pDNA with lipofectamine, protamine
and LD4 according to the procedure described in the Materials and methods section.
Error bars indicate standard deviation between six replicates.
Fig. 7. A: Gene transfer to HeLa cells mediated by pDNA:LC8 and pDNA:LD4 complexes.
Transfection efﬁciency was assessed by measuring the activity of the luciferase report-
er gene. B: Comparison of the transfection efﬁciency of the LD4 fusion protein with the
traditional delivery vectors PEI and Lipofectamine™. The combination of proteins (LD4
and protamine) with Lipofectamine™, resulting in ternary vectors, was also evaluated.
Error bars indicate standard deviation between triplicates.
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construct a modular fusion protein speciﬁcally designed for gene de-
livery. The modiﬁed LC8, named LD4, was able to: i) interact and con-
dense pDNA in vitro forming positively charged complexes and ii) to
interact in vitro with dynein intermediate chain, conﬁrming its func-
tionality. Despite still far from being an optimized vector like the
commercial lipids Lipofectamine™, LD4 proved to be 30-fold more ef-
ﬁcient in transfection than protamine and 485-fold more efﬁcient
than naked DNA – this one the delivery method used in most of the
non-viral clinical trials conducted so far. Transfection and cytotoxity
assays also indicated that LD4 can be associated to cationic lipids to
generate even more efﬁcient delivery vectors for in vitro applications.
Pre-treatment of the transfected HeLa cells with different drugs
showed a major involvement of the cell's cytoskeleton in the intracel-
lular trafﬁcking, indicating the involvement of the dynein molecular
motor in the transport of the pDNA:LD4 complexes. Despite the trans-
fection results found using the LD4 vector are promising, the results
also indicate the possibility of different forms of vector optimization,
particularly particle charge and the ability to escape from endosomes/
lysosomes. Finally, we believe that the work presented here add new
information on the development of recombinant modular proteins
speciﬁcally designed for gene delivery. By taking advantage of strate-
gies used by virus to infect mammalian cells these vectors may, in the
near future, increase the efﬁciency of non viral vectors and provide
new tools for DNA vaccination and gene therapy studies.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.jconrel.2012.01.011.
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